Last updated on October 2020

A Study of XmAb 22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors

Brief description of study

This is a Phase 1, multiple dose, ascending-dose escalation study and expansion study designed to define a maximum tolerated dose and/or recommended dose of XmAb22841 monotherapy and in combination with pembrolizumab; to assess safety, tolerability, pharmacokinetics, immunogenicity, and anti-tumor activity of XmAb22841 monotherapy and in combination with pembrolizumab in subjects with select advanced solid tumors.

Clinical Study Identifier: NCT03849469

Find a site near you

Start Over

Emory University

Atlanta, GA United States
  Connect »

UCLA Hematology & Oncology Clinic

Los Angeles, CA United States
  Connect »

Karmanos Cancer Institute

Detroit, MI United States
  Connect »

Barnes-Jewish Hospital

Saint Louis, MO United States
  Connect »

Siteman Cancer Center - St. Peters

Saint Peters, MO United States
  Connect »

UPMC Hillman Cancer Center

Pittsburgh, PA United States
  Connect »

UPMC Shadyside Hospital

Pittsburgh, PA United States
  Connect »

UCSD Perlman Medical Offices

La Jolla, CA United States
  Connect »

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.